Dashboard
1
Poor Management Efficiency with a low ROCE of 22.33%
- The company has been able to generate a Return on Capital Employed (avg) of 22.33% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -1.18% and Operating profit at -0.71% over the last 5 years
4
With a fall in Net Sales of -35.71%, the company declared Very Negative results in Jun 26
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,144 Million (Mid Cap)
15.00
NA
4.86%
-0.44
8.37%
1.42
Revenue and Profits:
Net Sales:
146 Million
(Quarterly Results - Jun 2026)
Net Profit:
36 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.98%
0%
2.98%
6 Months
-18.52%
0%
-18.52%
1 Year
-30.52%
0%
-30.52%
2 Years
9.89%
0%
9.89%
3 Years
-37.44%
0%
-37.44%
4 Years
-46.93%
0%
-46.93%
5 Years
-52.23%
0%
-52.23%
Wuhan Keqian Biology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.18%
EBIT Growth (5y)
-0.71%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.24
Tax Ratio
13.07%
Dividend Payout Ratio
70.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.23%
ROE (avg)
12.82%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.28
EV to EBIT
10.98
EV to EBITDA
8.73
EV to Capital Employed
1.50
EV to Sales
3.91
PEG Ratio
NA
Dividend Yield
5.41%
ROCE (Latest)
13.62%
ROE (Latest)
8.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
146.30
227.50
-35.69%
Operating Profit (PBDIT) excl Other Income
38.70
99.70
-61.18%
Interest
0.10
0.10
Exceptional Items
16.00
2.40
566.67%
Consolidate Net Profit
36.00
78.70
-54.26%
Operating Profit Margin (Excl OI)
47.00%
298.30%
-25.13%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -35.69% vs 7.36% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -54.26% vs -1.99% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
946.10
938.50
0.81%
Operating Profit (PBDIT) excl Other Income
479.50
417.50
14.85%
Interest
0.20
5.00
-96.00%
Exceptional Items
32.00
27.30
17.22%
Consolidate Net Profit
416.90
381.50
9.28%
Operating Profit Margin (Excl OI)
386.70%
327.90%
5.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.81% vs -11.23% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 9.28% vs -3.56% in Dec 2024
About Wuhan Keqian Biology Co., Ltd. 
Wuhan Keqian Biology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






